Overexpression of Stathmin 1 Predicts Poor Prognosis and Promotes Cancer Cell Proliferation and Migration in Ovarian Cancer

Overview

Journal Dis Markers

Publisher Wiley

Specialty Biochemistry

Date 2022 Feb 21

PMID 35186166

Authors

Lekai Nie

Chen Zhang

Haiyun Song

Qianqian Zhao

Lei Cheng

Peihai Zhang

Xingsheng Yang

Affiliations

Soon will be listed here.

Abstract

Purpose: The aim of this study was to investigate the expression of stathmin 1 (STMN1) in ovarian cancer and its effect on prognosis. The effect and mechanism of STMN1 on the proliferation and migration of ovarian cancer cells were also investigated.

Methods: Expression of STMN1 was measured by immunohistochemical staining in ovarian cancer tissues. The effects of STMN1 on the proliferation and migration capacity of ovarian cancer were evaluated using Cell Counting Kit-8 (CCK-8) assays, colony formation assays, immunofluorescence staining, wound healing assays, and Transwell assays. Transcription factors were predicted by bioinformatic analysis of TCGA database.

Results: STMN1 was upregulated in ovarian cancer tissues as compared to paracancerous tissues and associated with shorter overall survival. STMN1 expression significantly correlated with FIGO staging and tumor differentiation ( < 0.05). Furthermore, STMN1 promoted proliferation and migration in ovarian cancer cell lines. Bioinformatic analysis revealed that STMN1 was potentially regulated by E2F transcription factors. Then, we found that E2F1 regulated the expression of STMN1 and affected proliferation.

Conclusion: STMN1 is overexpressed in ovarian cancer, and its high expression suggests a poor prognosis. STMN1 promotes the proliferation and migration of ovarian cancer and is regulated by E2F1. Thus, STMN1 may serve as a negative prognostic factor and possible target for the treatment of ovarian cancer patients.

Citing Articles

Biological roles of THRAP3, STMN1 and GNA13 in human blood cancer cells.

Alsagaby S 3 Biotech. 2024; 14(10):248.

PMID: 39345963 PMC: 11424602. DOI: 10.1007/s13205-024-04093-5.

Identification of RTP4 facilitating ovarian cancer by bioinformatics analysis and experimental validation.

Fang C, Han W, Tang C, Shen J, Ni B Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39249504 DOI: 10.1007/s00210-024-03421-z.

Epigenetically associated IGF2BP3 upregulation promotes cell proliferation by regulating E2F1 expression in hepatocellular carcinoma.

Liu C, Zhuo Y, Yang X, Yang C, Shu M, Hou B Sci Rep. 2024; 14(1):16051.

PMID: 38992083 PMC: 11239653. DOI: 10.1038/s41598-024-67021-w.

Adipocyte-derived CCDC3 promotes tumorigenesis in epithelial ovarian cancer through the Wnt/ß-catenin signalling pathway.

Wang F, Jin F, Peng S, Li C, Wang L, Wang S Biochem Biophys Rep. 2023; 35:101507.

PMID: 37601453 PMC: 10439399. DOI: 10.1016/j.bbrep.2023.101507.

The effects of the prognostic biomarker SAAL1 on cancer growth and its association with the immune microenvironment in lung adenocarcinoma.

Tong S, Jiang N, Wan J, Chen C, Wang S, Wu C BMC Cancer. 2023; 23(1):275.

PMID: 36973678 PMC: 10041717. DOI: 10.1186/s12885-023-10741-5.

References

Eggink L, Roby K, Cote R, Hoober J . An innovative immunotherapeutic strategy for ovarian cancer: CLEC10A and glycomimetic peptides. J Immunother Cancer. 2018; 6(1):28. PMC: 5905120. DOI: 10.1186/s40425-018-0339-5. View

Hsu H, Li C, Lee S, Wu W, Chen T, Chang K . Overexpression of stathmin 1 confers an independent prognostic indicator in nasopharyngeal carcinoma. Tumour Biol. 2013; 35(3):2619-29. DOI: 10.1007/s13277-013-1345-3. View

Horwitz S . Taxol (paclitaxel): mechanisms of action. Ann Oncol. 1994; 5 Suppl 6:S3-6. View

Menon U, Gentry-Maharaj A, Burnell M, Singh N, Ryan A, Karpinskyj C . Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2021; 397(10290):2182-2193. PMC: 8192829. DOI: 10.1016/S0140-6736(21)00731-5. View

Watanabe A, Suzuki H, Yokobori T, Tsukagoshi M, Altan B, Kubo N . Stathmin1 regulates p27 expression, proliferation and drug resistance, resulting in poor clinical prognosis in cholangiocarcinoma. Cancer Sci. 2014; 105(6):690-6. PMC: 4317896. DOI: 10.1111/cas.12417. View

Matulonis U, Sood A, Fallowfield L, Howitt B, Sehouli J, Karlan B . Ovarian cancer. Nat Rev Dis Primers. 2016; 2:16061. PMC: 7290868. DOI: 10.1038/nrdp.2016.61. View

Chen Y, Uen Y, Li C, Horng K, Chen L, Wu W . The E2F transcription factor 1 transactives stathmin 1 in hepatocellular carcinoma. Ann Surg Oncol. 2012; 20(12):4041-54. DOI: 10.1245/s10434-012-2519-8. View

Fan K, Zhang D, Li M, Shen S, Wang J, Ni X . Carboxyl-terminal polypeptide fragment of MUC16 combing stathmin1 promotes gallbladder cancer cell migration and invasion. Med Oncol. 2020; 37(12):114. DOI: 10.1007/s12032-020-01438-x. View

Perren T, Swart A, Pfisterer J, Ledermann J, Pujade-Lauraine E, Kristensen G . A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011; 365(26):2484-96. DOI: 10.1056/NEJMoa1103799. View

10.

Tamura K, Yoshie M, Miyajima E, Kano M, Tachikawa E . Stathmin Regulates Hypoxia-Inducible Factor-1α Expression through the Mammalian Target of Rapamycin Pathway in Ovarian Clear Cell Adenocarcinoma. ISRN Pharmacol. 2013; 2013:279593. PMC: 3683482. DOI: 10.1155/2013/279593. View

11.

Chun J, Cho M, Park S, So I, Jeon J . The conflicting role of E2F1 in prostate cancer: A matter of cell context or interpretational flexibility?. Biochim Biophys Acta Rev Cancer. 2019; 1873(1):188336. DOI: 10.1016/j.bbcan.2019.188336. View

12.

Zhang D, Dai L, Yang Z, Wang X, LanNing Y . Association of STMN1 with survival in solid tumors: A systematic review and meta-analysis. Int J Biol Markers. 2019; 34(2):108-116. DOI: 10.1177/1724600819837210. View

13.

Ying L, Su D, Zhu J, Ma S, Katsaros D, Yu H . Genotyping of stathmin and its association with clinical factors and survival in patients with ovarian cancer. Oncol Lett. 2013; 5(4):1315-1320. PMC: 3629093. DOI: 10.3892/ol.2013.1144. View

14.

Bao P, Yokobori T, Altan B, Iijima M, Azuma Y, Onozato R . High STMN1 Expression is Associated with Cancer Progression and Chemo-Resistance in Lung Squamous Cell Carcinoma. Ann Surg Oncol. 2017; 24(13):4017-4024. DOI: 10.1245/s10434-017-6083-0. View

15.

Zhang X, Ji J, Yang Y, Zhang J, Shen L . Stathmin1 increases radioresistance by enhancing autophagy in non-small-cell lung cancer cells. Onco Targets Ther. 2016; 9:2565-74. PMC: 4857807. DOI: 10.2147/OTT.S100468. View

16.

Balachandran R, Welsh M, Day B . Altered levels and regulation of stathmin in paclitaxel-resistant ovarian cancer cells. Oncogene. 2003; 22(55):8924-30. DOI: 10.1038/sj.onc.1207060. View

17.

Feng W, Xiaoyan X, Xuan Y, Xiangke L, Zichang Y, Ran Z . Silencing stathmin-modulating efficiency of chemotherapy for esophageal squamous cell cancer with paclitaxel. Cancer Gene Ther. 2015; 22(3):115-21. DOI: 10.1038/cgt.2014.74. View

18.

Su D, Smith S, Preti M, Schwartz P, Rutherford T, Menato G . Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel. Cancer. 2009; 115(11):2453-63. DOI: 10.1002/cncr.24282. View

19.

Wang J, Ni X, Shen S, Zhang D, Ni X, Suo T . Phosphorylation at Ser10 triggered p27 degradation and promoted gallbladder carcinoma cell migration and invasion by regulating stathmin1 under glucose deficiency. Cell Signal. 2021; 80:109923. DOI: 10.1016/j.cellsig.2021.109923. View

20.

Bai T, Yokobori T, Altan B, Ide M, Mochiki E, Yanai M . High STMN1 level is associated with chemo-resistance and poor prognosis in gastric cancer patients. Br J Cancer. 2017; 116(9):1177-1185. PMC: 5418450. DOI: 10.1038/bjc.2017.76. View